Lee Swem is cur­rent­ly the Chief Devel­op­ment Offi­cer at Kan­vas Bio­sciences, where he leads the devel­op­ment of micro­bial LBP prod­ucts. The company’s clin­i­cal devel­op­ment pro­grams are focused on micro­bio­me-based treat­ments for severe unmet needs in humans. 

Lee Swem was pre­vi­ous­ly Chief Sci­en­tif­ic Offi­cer at Fed­er­a­tion Bio, which he helped launch in Jan­u­ary 2019 with founders from Stan­ford Uni­ver­si­ty and Ven­rock. He suc­cess­ful­ly led the com­pa­ny through a Seed ($10M) and Series A ($50M) financ­ing pri­or to the assets being acquired by Kan­vas Bio­sciences. Pri­or to this posi­tion, Lee served as Senior Vice Pres­i­dent and Chief Sci­en­tif­ic Offi­cer, Vice Pres­i­dent of Research, and Direc­tor of the Ther­a­peu­tic Anti­body Pro­gram at Achao­gen from 2014 to 2018. Before join­ing Achao­gen, Lee was a Sci­en­tist in the Depart­ment of Infec­tious Dis­ease at Genen­tech. Dur­ing his tenure at Genen­tech, Lee start­ed and led the anti-influen­za A pro­gram, the anti-influen­za B pro­gram, and began a small mol­e­cule anti-bac­te­r­i­al program. 

Lee received his Ph.D. from Indi­ana Uni­ver­si­ty. Lee has authored sev­er­al INDs and over 25 patents and publications.